Initial Risk Assessment as part of the Quality by Design in peptide drug containing formulation development

Area of Science:

• Pharmaceutical Science
• Drug Delivery Systems
• Biotechnology

Background:

• Quality by Design (QbD) and Risk Assessment (RA) are integral to modern pharmaceutical development, mandated by regulatory bodies.
• Oral peptide formulations present unique challenges due to stability and bioavailability issues.

Purpose of the Study:

• To implement QbD principles and RA in the early development of oral peptide formulations.
• To demonstrate a practical case study of QbD and RA for Liraglutide-encapsulated polymeric nanoparticles for type 2 Diabetes Mellitus treatment.

Main Methods:

• Applied QbD thinking and RA methodology from the initial stages of oral peptide formulation development.
• Utilized a case study focusing on Liraglutide-loaded nanoparticles, identifying critical quality attributes (CQAs) and critical material attributes (CMAs).
• Evaluated process parameters, including sonication time and power, for their impact on product quality.

Main Results:

• Identified particle size, encapsulation efficiency, and drug loading as critical quality attributes for Liraglutide nanoparticles.
• Determined that polymer concentration, drug concentration, w2/o ratio, stabilizer concentration, and polymer type were critical material attributes impacting product quality.
• Selected sonication time and power as the most critical process elements.

Conclusions:

• Emphasized the importance of risk-factor-focused development in oral peptide pharmaceutical formulations.
• Highlighted the necessity of thorough planning and risk prioritization to optimize resource allocation for achieving desired product quality in oral peptide delivery systems.